Lorinden A, 15 g

1 g of ointment for external use contains: 

Active substances:

flumethasone pivalate 200 mcg,

salicylic acid 30 mg.

Excipients: 

propylene glycol,

lanolin anhydrous,

petroleum jelly white.

Lorinden A is a combined preparation with anti-inflammatory and keratolytic action for external use.

Flumethasone pivalate - synthetic corticosteroids, has anti-inflammatory, anti-edema, anti-allergic, antipruritic effect. Inhibits the activity of phospholipase A2, which leads to suppression of the synthesis of prostaglandins and leukotrienes, inhibits the release of inflammatory mediators.

It inhibits the migration of leukocytes and lymphocytes to the inflammation focus. Prevents marginal accumulation of neutrophils, which leads to a decrease in inflammatory exudate, production of cytokines and inhibition of macrophage migration, as a result of which infiltration and granulation processes decrease. It inhibits the proteolytic activity of tissue kinins, inhibits the growth of fibroblasts, and prevents the development of connective tissue in the focus of inflammation. Reduces hyperemia, manifestations of hypersensitivity reactions, proliferative and exudative processes occurring in the connective tissue in the focus of inflammation.

Salicylic acid - NSAIDs, promotes the penetration of corticosteroids and gives the drug additional anti-parakeratotic, moderate keratolytic and local hypothermic properties, promotes the penetration of flumethasone into the skin. In addition, it has antibacterial and fungicidal properties and restores the protective function of the skin. Suppresses the secretion of the sebaceous and sweat glands.

Pharmacokinetics  

Suction

The absorption of flumethasone pivalate is higher in children than in adults and increases when used in the area of ​​skin folds, on the face, on skin with damaged epidermis and skin affected by the inflammatory process, under occlusive dressings, when applied to large areas of the skin (in this case, it can cause systemic action).

Distribution

Due to the external route of application and the keratolytic action of salicylic acid, flumethasone pivalate easily penetrates into the stratum corneum, through the keratinous layers of the skin, where it accumulates.

Metabolism

Flumethasone pivalate is practically not metabolized in the skin. After slight absorption into the systemic circulation of flumethasone, pivalate is biotransformed in the liver.

Withdrawal

It is excreted in the urine and, to a lesser extent, with bile in the form of compounds with glucuronic acid, as well as in small amounts unchanged.

Lorinden A ointment is prescribed for:

• eczema - subacute or chronic;
• diffuse neurodermatitis;
• atopic dermatitis;
• hyperkeratosis;
• psoriasis
• chronic dyshidrosis;
• red flat lichen;
• seborrhea;
• photodermatitis;
• pruritus with lichenification;
• blistering skin diseases;
• red warty lichen;
• discoid lupus erythematosus;
• exudative erythema;
• insect bites.

It is not recommended to use the drug for patients suffering from:

• bacterial, fungal and viral skin lesions;
• tuberculosis of the skin;
• exudative stages of skin diseases;
• syphilis with cutaneous manifestations;
• precancerous conditions and skin neoplasms;
• eels.

In addition, one should refrain from using the ointment at the beginning of pregnancy, with trophic ulcers from varicose veins, with hypersensitivity and in childhood. Observance of caution requires the treatment of patients with a diagnosis of renal failure, since the danger of nephrotoxic action of significant doses of salicylates remains.

Local reactions: possible - burning, itching, dry skin; with prolonged use - skin atrophy, local hirsutism, telangiectasia, purpura, steroid acne, perioral dermatitis, pigmentation disorders.

Systemic reactions: with prolonged use, application to large areas of the skin and / or the use of occlusive dressings, side effects characteristic of GCS are possible.

With external use of the drug Lorinden A on the skin of the eyelids, in the future, sometimes, the development of cataracts or glaucoma is possible.

During treatment with the drug, vaccination and immunization are contraindicated due to the immunosuppressive effect of the drug.

Should not be administered in combination with other topical preparations.

With systemic absorption of the drug, GCS reduces the effect of insulin, oral hypoglycemic agents, antihypertensive drugs, anticoagulants, and reduces the concentration of praziquantel in the blood serum.

The combination of Lorinden A with the following drugs increases the risk of side effects: androgens, estrogens, oral contraceptives, anabolic steroids (hirsutism, acne), antipsychotics, bukarban, azathioprine (cataract), anticholinergic antagonists, antihistamines, nitric acid drugs, tricyclic drugs ), diuretics (hypokalemia), cardiac glycosides (digitalis intoxication).

Outwardly.

The ointment is applied in a thin layer on the skin in the affected area 2-3 times / day. After the removal of acute inflammation, the drug is used 1-2 times / day. After the complete disappearance of painful manifestations, treatment is carried out for another 3-4 days. For chronic skin lesions, treatment should not be continued for more than 3 weeks.

The ointment can also be applied in the form of an occlusive dressing, which should be changed every 24-48 hours. layer according to the therapeutic requirements specific to each individual case.

Symptoms: extremely rarely, when used on very large areas of the skin, systemic manifestations of GCS and / or symptoms of salicylate poisoning are possible.

Lorinden A is an adequate drug for the treatment of lesions on dry and fat-free areas of the skin, characterized by severe infiltration, lichenification, desquamation and hyperkeratosis, as well as callousness; easy to apply, adheres well to dry skin, increases its fat content and promotes moisture retention. The degree of moisture can be adjusted by the thickness of the applied layer, according to the therapeutic requirements specific to each individual case.

It is contraindicated to apply the drug to the skin of the face. It is necessary to ensure that the drug does not get on the mucous membranes and conjunctiva.

It is not recommended to exceed the course of treatment. With prolonged use of the ointment on large areas of the skin, the frequency of side effects increases.

When an infection occurs at the site of application of the ointment, agents with a more pronounced antibacterial or antifungal effect should be used.

It should be used with caution in persons with atrophic skin changes, especially in elderly patients.

The ointment does not stain clothes and bedding.

- Application for impaired renal function Avoid repeated application to large areas of the skin in patients with severe renal failure (systemic effect of salicylic acid is possible).

- Use in pediatrics In children, the drug is used only when absolutely necessary, in a short course, on small surfaces of the body.

- Influence on the ability to drive vehicles and control mechanisms

The drug does not limit psychophysical activity, the ability to drive vehicles and service moving mechanisms.

Ointment